Meropenem Versus Piperacillin-Tazobactam as Empiric Therapy for Febrile Neutropenia in Pediatric Oncology Patients

• DOI: 10.7314/apjcp.2014.15.11.4549
• Publication Date: 2014-09-29T02:34:40Z
• Authors: Gulay Sezgin; Can Acipayam; Ayse Ozkan; Ibrahim Bayram; Atila Tanyeli
• Keywords: Piperacillin/tazobactam; Tazobactam; Absolute neutrophil count; Empiric therapy; Pediatric cancer

Infection is a serious cause of mortality in febrile neutropenia pediatric cancer patients. Recently, monotherapy has replaced the combination therapy empirical treatment neutropenia. Since there been no reported trial comparing efficacy meropenem and piperacillin-tazobactam (PIP/ TAZ) monotherapies, present retrospective study was conducted to compare safety neutropenic children with cancer.Charts febrile, hospitalized at our center between March 2008 April 2011 for hemato-oncological malignancies were reviewed. Patients received PIP/TAZ 360 mg/kg/day or 60 intravenously three divided doses. Duration fever neutropenia, absolute neutrophil count, modification, success rate compared two groups. Resolution without antibiotic change defined as resolution death patient failure. Modification changing antimicrobial agent during episode.Two hundred eighty four episodes documented 136 patients median age 5 years. In 198 86 PIP/ TAZ used. sex, primary disease not different Success rates modification groups showed significant differences (p>0.05). Overall 92.4% 91.9% respectively. No adverse effects occurred either groups.Meropenem are equally safe effective initial cancer.